miR-143, miR-222, and miR-452 Are Useful as Tumor Stratification and Noninvasive Diagnostic Biomarkers for Bladder Cancer

Puerta, Patricia; García-Baquero, Rodrigo; Jia, Angela Y.; Ocaña, Sara; Álvarez-Múgica, M.; Álvarez-Ossorio, J.L.; Cordon‐Cardo, Carlos; Cava, Fernando; Sänchez‐Carbayo, Marta

doi:10.1016/j.ajpath.2012.01.034

Cited by 140 publications

(110 citation statements)

References 29 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…23,24 Studies on mRNA and miRNA expression in UC have also been carried out using RT-PCR and genomic microarrays, and have uncovered expression profiles linked to disease outcome. [25][26][27][28] There has been considerable interest in the mutational status of the tumor suppressor gene TP53 as a prognostic factor and guide to surgical management of the disease. 29,30 Although TP53 single gene sequence assays have been applied to UC, most laboratories have used IHC to detect the expression of presumed mutant TP53 protein to help guide treatment planning in some cases.…”

mentioning

confidence: 99%

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

Wang²,

et al. 2014

View full text Add to dashboard Cite

Although urothelial carcinoma (UC) of the urinary bladder generally portends a favorable prognosis, metastatic tumors often follow an aggressive clinical course. DNA was extracted from 40 lm of formalin-fixed, paraffinembedded (FFPE) sections from 35 stage IV UCs that had relapsed and progressed after primary surgery and conventional chemotherapy. Next-generation sequencing (NGS) was performed on hybridization-captured, adaptor ligation-based libraries for 3320 exons of 182 cancer-related genes plus 37 introns from 14 genes frequently rearranged in cancer to at an average sequencing depth of 1164 Â and evaluated for all classes of genomic alterations (GAs). Actionable GAs were defined as those impacting the selection of targeted anticancer therapies on the market or in registered clinical trials. A total of 139 GAs were identified, with an average of 4.0 GAs per tumor (range 0-10), of which 78 (56%) were considered actionable, with an average of 2.2 per tumor (range 0-7). Twenty-nine (83%) cases harbored at least one actionable GA including: PIK3CA (9 cases; 26%); CDKN2A/B (8 cases; 23%); CCND1 (5 cases; 14%); FGFR1 (5 cases; 14%); CCND3 (4 cases; 11%); FGFR3 (4 cases; 11%); MCL1 (4 cases; 11%); MDM2 (4 cases; 11%); EGFR (2 cases, 6%); ERBB2 (HER2/neu) (2 cases, 6%); NF1 (2 cases, 6%) and TSC1 (2 cases, 6%). Notable additional alterations included TP53 (19 cases, 54%) and RB1 (6 cases; 17%). Genes involved in chromatin modification were altered by nonsense mutation, splice site mutation or frameshift indel in a mutually exclusive manner in nearly half of all cases including KDM6A (10 cases; 29%) and ARID1A (7 cases; 20%). Comprehensive NGS of 35 UCs of the bladder revealed a diverse spectrum of actionable GAs in 83% of cases, which has the potential to inform treatment decisions for patients with relapsed and metastatic disease.

show abstract

mentioning

confidence: 99%

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

Wang²,

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In addition, miRNAs have been reported to be stable in the urine and also show high specificity and sensitivity (95,(101)(102)(103). These characteristics indicate that urinary miRNAs are a potential biomarker for bladder cancer and UC screening.…”

Section: Urine Mirna Detection In Urological Cancermentioning

confidence: 89%

“…In other studies, miR-452 and miR-222 were reported to play an oncogenic role, while miR-143 was able to function as a tumor suppressor (103,(105)(106)(107). The present study also revealed that miR-452 may contribute to tumorigenesis and aid in bladder cancer diagnostics, whereas miR-143 and miR-222 may be related to tumor progression and may be used for clinical outcome assessment (103,107). In addition, expression levels of of miR-222 and miR-452 were inversely correlated with ERBB4 expression, while ERBB4 was localized to several cellular counterparts, including the membrane (108), cytoplasm (108) and nucleus (109).…”

Section: Urine Mirna Detection In Urological Cancermentioning

confidence: 91%

microRNA detection in feces, sputum, pleural effusion and urine: Novel tools for cancer screening (Review)

et al. 2013

View full text Add to dashboard Cite

Abstract. microRNAs (miRNAs) are short non-coding RNA sequences that play important roles in the regulation of gene expression. They have significant regulatory functions in basic cellular processes, including differentiation, proliferation and apoptosis. miRNAs are differentially expressed in tumors, compared with normal tissues. Importantly, miRNAs are also stable and abundantly present in body fluids and feces. The high reproducibility, sensitivity and specificity of miRNAs in body fluids and feces enable miRNAs to be used as potential molecular markers for cancer screening. An increasingly large number of research studies have reported the role of miRNAs in this field. In the present review, we focused mainly on the application of detecting miRNAs in stool, sputum, pleural effusion and urine, to detect colon, lung and urological cancers, highlighting the role of miRNAs in early diagnosis and prognosis. IntroductionCancer is currently the most lethal human disease. Lung and colorectal cancers are the first and third most common types of cancers and the leading causes of cancer-related mortality worldwide (1). Bladder cancer, a urological cancer, is the second most common malignancy that involves the urinary system, and the clinical outcome is often poor once the tumor becomes invasive (2). Although much progress has been made in the prevention, early diagnosis and treatment of cancer, survival rates are still not optimistic, indicating that a more powerful method to detect cancer in the early stages is needed. Early detection of cancer has been reported to greatly improve both the survival rate and prognosis, suggesting that the key to oncotherapy may lie in early diagnosis (3-7). Thus, developing a method for the early detection of cancer is both important and necessary. Ideally, an early detection method would have high sensitivity, specificity and repeatability, and would be safe, affordable and acceptable to the patient as well.Traditional methods, such as colonoscopy (8), bronchoscopy (9) and cystoscopy (10), are used to detect colon cancer, non-small cell lung cancer (NSCLC) and bladder cancer, respectively. These methods have greatly benefited many individuals in the past and they are still used to diagnose cancer. However, their use has been hampered by their invasive nature, the manpower resources they require, their high cost and the discomfort they cause patients (11-13).Biological screening methods, including the fecal occult blood test (FOBT) for colon cancer; sputum cytology for NSCLC (14); and the bladder tumor antigen (BTA test), BTA stat test, nuclear matrix protein 22 (NMP22), and urinary cytology for bladder cancer, have also been applied in recent years. However, these methods each have a significant sensitivity (15,16) or specificity (13), but not both.As previously mentioned, these methods have drawbacks that prevent their wide application.

show abstract

“…Many recent reports demonstrated that circulating miRNAs levels were significantly increased in cancer plasma or serum samples compared to control groups (31)(32)(33)(34)(35), including NSCLC (36,37). But some miRNAs expressions are lower in cancer groups than in control groups.…”

Section: Discussionmentioning

confidence: 99%

MicroRNAs in Body Fluids as Biomarkers for Non-Small Cell Lung Cancer: A Systematic Review

Huang

Deng

et al. 2014

Technol Cancer Res Treat

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is one of the most common life-threatening malignant tumors. A test for early diagnosis of NSCLC needs to be not too invasive and not too heavy a burden for weakened patients. A series of studies reported various microRNAs (miRNAs) could be novel serum biomarkers for NSCLC. However, the diagnostic ability of different miRNA biomarkers varies among the reports. The goal of this study was to perform a systematic review to examine the effect of miRNAs on NSCLC-related outcomes. We system- The range of diagnostic odds ratio (DOR) was 6.52983.38. The current evidence indicates that miRNAs in body fluids show high accuracy in identifying NSCLC, and could be a useful screening tool for diagnosing NSCLC patients.

show abstract

miR-143, miR-222, and miR-452 Are Useful as Tumor Stratification and Noninvasive Diagnostic Biomarkers for Bladder Cancer

Cited by 140 publications

References 29 publications

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

microRNA detection in feces, sputum, pleural effusion and urine: Novel tools for cancer screening (Review)

MicroRNAs in Body Fluids as Biomarkers for Non-Small Cell Lung Cancer: A Systematic Review

Contact Info

Product

Resources

About